Fesoterodine (fumarate)

Fesoterodine (fumarate)

• CAS Number: 286930-03-8
• UNSPSC Description: Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB)[1][2].
• Target Antigen: mAChR
• Type: Reference compound
• Related Pathways: GPCR/G Protein;Neuronal Signaling
• Field of Research: Metabolic Disease; Neurological Disease; Cancer
• Assay Protocol: https://www.medchemexpress.com/Fesoterodine-fumarate.html
• Purity: 99.73
• Solubility: DMSO : 100 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
• Smiles: OCC1=CC([C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2)=C(C=C1)OC(C(C)C)=O.OC(/C=C/C(O)=O)=O
• Molecular Weight: 527.65
• References & Citations: [1]Ellsworth P, et al. Fesoterodine for the treatment of urinary incontinence and overactive bladder. Ther Clin Risk Manag. 2009;5:869-76. Epub 2009 Nov 18.|[2]Didem Yilmaz-Oral, et al. The Beneficial Effect of Fesoterodine, a Competitive Muscarinic Receptor Antagonist on Erectile Dysfunction in Streptozotocin-induced Diabetic Rats.|[3]Peter Ney, et al. Pharmacological Characterization of a Novel Investigational Antimuscarinic Drug, Fesoterodine, in Vitro and in Vivo. BJU Int. 2008 Apr;101(8):1036-42.|[4]Martin C Michel, et al. Fesoterodine: A Novel Muscarinic Receptor Antagonist for the Treatment of Overactive Bladder Syndrome. Expert Opin Pharmacother. 2008 Jul;9(10):1787-96.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, stored under nitrogen)
• Clinical Information: Launched